Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Geniculate Artery Embolization for Recurrent Effusion After Total Knee Arthroplasty in a Patient With Hemophilia.

Cureus·2026
Same author

Emergency mitral valve transcatheter edge-to-edge repair in cardiogenic shock due to papillary muscle rupture.

Journal of cardiology cases·2026
Same author

Stem Cell and Cell-Free Strategies for Osteoarthritis: Toward Durable Regenerative Therapies.

Stem cells international·2026
Same author

Control of cell division by an <i>Acinetobacter baumannii</i> protein with a novel nucleotidyl-cyclase-like fold.

bioRxiv : the preprint server for biology·2026
Same author

Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer.

Clinical genitourinary cancer·2026
Same author

Urgent Transcatheter Edge-To-Edge Mitral Valve Repair in Cardiogenic Shock: A Case Series.

A&A practice·2026
Same journal

Eugene Braunwald, MD, 1929-2026.

Circulation·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same journal

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same journal

Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association.

Circulation·2026
Same journal

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same journal

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Circulation·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: May 13, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Maximizar la función ventricular con terapia génica basada en células multimodal basada en células.

Terrence M Yau1, Christopher Kim, Guangming Li

  • 1Division of Cardiovascular Surgery, Toronto General Hospital, Department of Surgery, University of Toronto, Heart & Stroke Foundation/Richard Lewar Centre of Excellence, Toronto, Ontario, Canada. terry.yau@utoronto.ca

Circulation
|September 15, 2005
PubMed
Resumen
Este resumen es generado por máquina.

Este estudio muestra que la combinación de la terapia génica con el factor de crecimiento endotelial vascular (VEGF) y el factor de crecimiento similar a la insulina I (IGF-I) con el trasplante de células de médula ósea (BMC) mejora la función cardíaca. Este enfoque multimodal mejora la supervivencia celular y reduce la muerte celular en cicatrices miocárdicas.

Más Videos Relacionados

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Videos de Experimentos Relacionados

Last Updated: May 13, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Área de la Ciencia:

  • Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular
  • La Medicina Regenerativa es una Medicina Regenerativa.
  • Terapia génica Terapia génica La terapia génica es una terapia genética.

Sus antecedentes:

  • El factor de crecimiento endotelial vascular (VEGF) mejora la angiogénesis en las cicatrices miocárdicas.
  • El factor de crecimiento similar a la insulina I (IGF-I) puede promover la hipertrofia e inhibir la apoptosis.
  • El trasplante de células de médula ósea (BMC) es una terapia potencial para el daño cardíaco.

Objetivo del estudio:

  • Para evaluar la eficacia de la terapia de IGF-I y VEGF multigénico basado en células.
  • Para evaluar el impacto en la función ventricular izquierda (LV), la supervivencia celular y la apoptosis.
  • Para determinar los beneficios después del trasplante de CMB en un modelo de infarto de miocardio en rata.

Principales métodos:

  • Las ratas de Lewis con infarto de miocardio inducido recibieron BMCs diseñadas para expresar VEGF, IGF-I o ambos.
  • La expresión génica, la supervivencia celular, la apoptosis y la función de LV se cuantificaron durante 4 semanas.
  • Las técnicas incluyeron PCR en tiempo real, tinción TUNEL, ecocardiografía y Western blotting.

Principales resultados:

  • La coexpresión de VEGF e IGF-I en los CMM aumentó significativamente los niveles de IGF-I y VEGF en el tejido cicatricial.
  • La supervivencia celular trasplantada fue más alta en el grupo VEGF + IGF-I.
  • La apoptosis se redujo, y la fracción de eyección de LV mejoró significativamente en el grupo de terapia génica combinada en comparación con los controles y los grupos de terapia génica única.

Conclusiones:

  • El trasplante de BMCs que expresan tanto VEGF como IGF-I reduce efectivamente la apoptosis y mejora la supervivencia de las células trasplantadas.
  • Este enfoque multimodal de terapia génica basada en células maximiza la recuperación de la función ventricular izquierda después del infarto de miocardio.
  • La terapia génica combinada es prometedora para mejorar los resultados en las estrategias de trasplante celular para las enfermedades del corazón.